Search Results | Diabetes | American Diabetes Association

1-20 of 23

Sort by

Sort Order Select

Meeting Abstracts

794-P: Predictors of Hemoglobin (Hb) and Its Changes Focusing on Anemia and Polycythemia after Administration of the SGLT2 Inhibitor Tofogliflozin

YASUHIRO MATSUBAYASHI, AKIHIRO YOSHIDA, HIDEKI SUGANAMI, KOHEI KAKU, HIROHITO SONE

Diabetes 2021;70(Supplement_1):794-P

DOI: https://doi.org/10.2337/db21-794-P

Published: 01 June 2021

View article

Meeting Abstracts

1133-P: Association of Higher Baseline BNP Levels with a Greater Reduction in Plasma Volume and Increase in Beta-Hydroxybutyrate via the SGLT2 Inhibitor Tofogliflozin in Type 2 Diabetes

AKIHIRO YOSHIDA, YASUHIRO MATSUBAYASHI, TOSHIAKI NOJIMA, HIDEKI SUGANAMI, MOMOKO OE, KAZUYA FUJIHARA, SHIRO TANAKA, KOHEI KAKU, HIROHITO SONE

Diabetes 2020;69(Supplement_1):1133-P

DOI: https://doi.org/10.2337/db20-1133-P

Published: 01 June 2020

View article

Meeting Abstracts

1125-P: Association of Plasma Volume with Body Weight and BNP after Long-Term Administration and Subsequent Withdrawal of the SGLT2 Inhibitor Tofogliflozin

YASUHIRO MATSUBAYASHI, AKIHIRO YOSHIDA, TOSHIAKI NOJIMA, HIDEKI SUGANAMI, KAZUYA FUJIHARA, KOHEI KAKU, HIROHITO SONE

Diabetes 2020;69(Supplement_1):1125-P

DOI: https://doi.org/10.2337/db20-1125-P

Published: 01 June 2020

View article

Meeting Abstracts

1435-P: Dulaglutide Exerts More Beneficial Antiatherosclerotic Effects in Early Phase of Diabetes than in Late Phase in ApoE Knockout Mice with Diabetes

JUNPEI SANADA, ATSUSHI OBATA, YOSHIYUKI OBATA, YOSHIRO FUSHIMI, TOMOKO IKEDA, YUKA NOGAMI, MASASHI SHIMODA, SHUHEI NAKANISHI, TOMOATSU MUNE, KOHEI KAKU, HIDEAKI KANETO

Diabetes 2020;69(Supplement_1):1435-P

DOI: https://doi.org/10.2337/db20-1435-P

Published: 01 June 2020

View article

Meeting Abstracts

2054-P: Combination of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor and Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Substantially Protects Pancreatic ß-Cells Especially in Early Phase of Diabetes Rather than Advanced Phase

YOSHIRO FUSHIMI, ATSUSHI OBATA, JUNPEI SANADA, YUKA NOGAMI, TOMOKO IKEDA, YOSHIYUKI OBATA, MASASHI SHIMODA, SHUHEI NAKANISHI, TOMOATSU MUNE, KOHEI KAKU, HIDEAKI KANETO

Diabetes 2020;69(Supplement_1):2054-P

DOI: https://doi.org/10.2337/db20-2054-P

Published: 01 June 2020

View article

Meeting Abstracts

1219-P: Enhanced Response in Serum Ketone Level in Men Compared with Women by Administration of SGLT2 Inhibitor

AKIHIRO YOSHIDA, YASUHIRO MATSUBAYASHI, TOSHIAKI NOJIMA, HIDEKI SUGANAMI, KOHEI KAKU, HIROHITO SONE

Diabetes 2019;68(Supplement_1):1219-P

DOI: https://doi.org/10.2337/db19-1219-P

Published: 01 June 2019

View article

Meeting Abstracts

1205-P: Baseline Lactate Level Is a Useful Predictor for Weight Loss after Long-Term SGLT2 Inhibitor Treatment

TOSHIAKI NOJIMA, YASUHIRO MATSUBAYASHI, AKIHIRO YOSHIDA, HIDEKI SUGANAMI, KOHEI KAKU, HIROHITO SONE

Diabetes 2019;68(Supplement_1):1205-P

DOI: https://doi.org/10.2337/db19-1205-P

Published: 01 June 2019

View article

Meeting Abstracts

1215-P: Adipose Tissue Insulin Resistance Predicts Ketosis via an SGLT2 Inhibitor

YASUHIRO MATSUBAYASHI, AKIHIRO YOSHIDA, TOSHIAKI NOJIMA, HIDEKI SUGANAMI, KAZUYA FUJIHARA, KOHEI KAKU, HIROHITO SONE

Diabetes 2019;68(Supplement_1):1215-P

DOI: https://doi.org/10.2337/db19-1215-P

Published: 01 June 2019

View article

Meeting Abstracts

Reduced Postprandial Hepatic Insulin Clearance via the DPP-4 Inhibitor Anagliptin Contributed to Improvement in Hyperglycemia in Patients with Type 2 Diabetes Mellitus

YASUHIRO MATSUBAYASHI, TAKAHIRO ABE, SAYAKA MURAGISHI, AKIHIRO YOSHIDA, HIDEKI SUGANAMI, KENICHI FURUSAWA, TAKAHO YAMADA, KAZUYA FUJIHARA, SHIRO TANAKA, KOHEI KAKU, HIROHITO SONE

Diabetes 2018;67(Supplement_1):1176-P

DOI: https://doi.org/10.2337/db18-1176-P

Published: 01 July 2018

View article

Meeting Abstracts

The SGLT2 Inhibitor Tofogliflozin Reduces Weight in People with Type 2 Diabetes due to Fluid Loss Initially and to Lipolysis in Late

AKIHIRO YOSHIDA, HIROMI KUSAKABE, TOSHINARI TAKAMURA, KOHEI KAKU, HIDEKI SUGANAMI

Diabetes 2018;67(Supplement_1):1152-P

DOI: https://doi.org/10.2337/db18-1152-P

Published: 01 July 2018

View article

Meeting Abstracts

Initial Beta-Hydroxybutyrate Elevation in Relation to Subsequent Weight Loss in Type 2 Diabetes via the SGLT2 Inhibitor Tofogliflozin

YUICHI SATO, KIYOHIDE NUNOI, KOHEI KAKU, AKIHIRO YOSHIDA, HIDEKI SUGANAMI

Diabetes 2018;67(Supplement_1):1156-P

DOI: https://doi.org/10.2337/db18-1156-P

Published: 01 July 2018

View article

Meeting Abstracts

Influence of SGLT2 Inhibitor on Resting Heart Rate (RHR) and Factors Related to Its Changes

YASUHIRO MATSUBAYASHI, TOSHIAKI NOJIMA, AKIHIRO YOSHIDA, HIDEKI SUGANAMI, TAKAHO YAMADA, KAZUYA FUJIHARA, SHIRO TANAKA, KOHEI KAKU, HIROHITO SONE

Diabetes 2018;67(Supplement_1):1154-P

DOI: https://doi.org/10.2337/db18-1154-P

Published: 01 July 2018

View article

Meeting Abstracts

Protective Effects of SGLT2 Inhibitor Luseogliflozin on Pancreatic Beta Cells in Obese Diabetic db/db Mice—"The Earlier and Longer, the Better”

TOMOHIKO KIMURA, MASASHI SHIMODA, SHUHEI NAKANISHI, TOMOATSU MUNE, KOHEI KAKU, HIDEAKI KANETO

Diabetes 2018;67(Supplement_1):2111-P

DOI: https://doi.org/10.2337/db18-2111-P

Published: 01 July 2018

View article

Meeting Abstracts

Effects of Different Types of Oral Glucose-Lowering Drugs on Hepatic Fat Accumulation and Liver Function in Japanese Subjects with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—A Randomized, Open-Label, 3-Arm Active-Control Study

TOMOE KINOSHITA, MASASHI SHIMODA, SHUHEI NAKANISHI, TOMOATSU MUNE, KOHEI KAKU, HIDEAKI KANETO

Diabetes 2018;67(Supplement_1):2050-P

DOI: https://doi.org/10.2337/db18-2050-P

Published: 01 July 2018

View article

Journal Articles

Replication Study for the Association Between Four Loci Identified by a Genome-Wide Association Study on European American Subjects With Type 1 Diabetes and Susceptibility to Diabetic Nephropathy in Japanese Subjects With Type 2 Diabetes

Shiro Maeda, Shin-ichi Araki, Tetsuya Babazono, Masao Toyoda, Tomoya Umezono, Koichi Kawai, Masahito Imanishi, Takashi Uzu, Hirotaka Watada, Daisuke Suzuki, Atsunori Kashiwagi, Yasuhiko Iwamoto, Kohei Kaku, Ryuzo Kawamori, Yusuke Nakamura

Diabetes 2010;59(8):2075–2079

DOI: https://doi.org/10.2337/db10-0067

Published: 11 May 2010

View article

Includes: Supplementary data

Journal Articles

Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 With Susceptibility to Type 2 Diabetes in a Japanese Population

Shintaro Omori, Yasushi Tanaka, Atsushi Takahashi, Hiroshi Hirose, Atsunori Kashiwagi, Kohei Kaku, Ryuzo Kawamori, Yusuke Nakamura, Shiro Maeda

Diabetes 2008;57(3):791–795

DOI: https://doi.org/10.2337/db07-0979

Published: 01 March 2008

View article

Includes: Supplementary data

Journal Articles

Genetic Variations in the Gene Encoding ELMO1 Are Associated With Susceptibility to Diabetic Nephropathy

Diabetes 2005;54(4):1171–1178

DOI: https://doi.org/10.2337/diabetes.54.4.1171

Published: 01 April 2005

View article

Includes: Supplementary data

Journal Articles

Association of Solute Carrier Family 12 (Sodium/Chloride) Member 3 With Diabetic Nephropathy, Identified by Genome-Wide Analyses of Single Nucleotide Polymorphisms

Nobue Tanaka, Tetsuya Babazono, Susumu Saito, Akihiro Sekine, Tatsuhiko Tsunoda, Masakazu Haneda, Yasushi Tanaka, Tomoaki Fujioka, Kohei Kaku, Ryuzou Kawamori, Ryuichi Kikkawa, Yasuhiko Iwamoto, Yusuke Nakamura, Shiro Maeda

Diabetes 2003;52(11):2848–2853

DOI: https://doi.org/10.2337/diabetes.52.11.2848

Published: 01 November 2003

View article

Journal Articles

Polymorphic Microsatellite Repeat Markers at the Glucokinase Gene Locus Are Positively Associated With NIDDM in Japanese

Kaoru Noda, Akira Matsutani, Yukio Tanizawa, Rosalind Neuman, Toshio Kaneko, M Alan Permutt, Kohei Kaku

Diabetes 1993;42(8):1147–1152

DOI: https://doi.org/10.2337/diab.42.8.1147

Published: 01 August 1993

View article

Journal Articles

Tolbutamide Inhibits cAMP-Dependent Phosphorylation of Liver 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase

Minoru Aoki, Kohei Kaku, Hiroshi Inoue, Akira Matsutani, Toshio Kaneko

Diabetes 1992;41(3):334–338

DOI: https://doi.org/10.2337/diab.41.3.334

Published: 01 March 1992

View article

NARROW

794-P: Predictors of Hemoglobin (Hb) and Its Changes Focusing on Anemia and Polycythemia after Administration of the SGLT2 Inhibitor Tofogliflozin

1133-P: Association of Higher Baseline BNP Levels with a Greater Reduction in Plasma Volume and Increase in Beta-Hydroxybutyrate via the SGLT2 Inhibitor Tofogliflozin in Type 2 Diabetes

1125-P: Association of Plasma Volume with Body Weight and BNP after Long-Term Administration and Subsequent Withdrawal of the SGLT2 Inhibitor Tofogliflozin

1435-P: Dulaglutide Exerts More Beneficial Antiatherosclerotic Effects in Early Phase of Diabetes than in Late Phase in ApoE Knockout Mice with Diabetes

2054-P: Combination of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor and Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Substantially Protects Pancreatic ß-Cells Especially in Early Phase of Diabetes Rather than Advanced Phase

1219-P: Enhanced Response in Serum Ketone Level in Men Compared with Women by Administration of SGLT2 Inhibitor

1205-P: Baseline Lactate Level Is a Useful Predictor for Weight Loss after Long-Term SGLT2 Inhibitor Treatment

1215-P: Adipose Tissue Insulin Resistance Predicts Ketosis via an SGLT2 Inhibitor

Reduced Postprandial Hepatic Insulin Clearance via the DPP-4 Inhibitor Anagliptin Contributed to Improvement in Hyperglycemia in Patients with Type 2 Diabetes Mellitus

The SGLT2 Inhibitor Tofogliflozin Reduces Weight in People with Type 2 Diabetes due to Fluid Loss Initially and to Lipolysis in Late

Initial Beta-Hydroxybutyrate Elevation in Relation to Subsequent Weight Loss in Type 2 Diabetes via the SGLT2 Inhibitor Tofogliflozin

Influence of SGLT2 Inhibitor on Resting Heart Rate (RHR) and Factors Related to Its Changes

Protective Effects of SGLT2 Inhibitor Luseogliflozin on Pancreatic Beta Cells in Obese Diabetic db/db Mice—"The Earlier and Longer, the Better”

Effects of Different Types of Oral Glucose-Lowering Drugs on Hepatic Fat Accumulation and Liver Function in Japanese Subjects with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—A Randomized, Open-Label, 3-Arm Active-Control Study

Replication Study for the Association Between Four Loci Identified by a Genome-Wide Association Study on European American Subjects With Type 1 Diabetes and Susceptibility to Diabetic Nephropathy in Japanese Subjects With Type 2 Diabetes

Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 With Susceptibility to Type 2 Diabetes in a Japanese Population

Genetic Variations in the Gene Encoding ELMO1 Are Associated With Susceptibility to Diabetic Nephropathy

Association of Solute Carrier Family 12 (Sodium/Chloride) Member 3 With Diabetic Nephropathy, Identified by Genome-Wide Analyses of Single Nucleotide Polymorphisms

Polymorphic Microsatellite Repeat Markers at the Glucokinase Gene Locus Are Positively Associated With NIDDM in Japanese

Tolbutamide Inhibits cAMP-Dependent Phosphorylation of Liver 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only